Core Viewpoint - The company, Xinmai Medical, has seen a stock price increase of 3.1% this week, closing at 97.98 yuan, with a total market capitalization of 12.077 billion yuan, ranking 27th in the medical device sector and 1716th in the A-share market [1] Company Announcements - Xinmai Medical's wholly-owned subsidiary, Shanghai Tuomai Medical Technology Co., Ltd., has received a medical device registration certificate for polyvinyl alcohol embolization microspheres, intended for the treatment of hypervascular solid organ malignant tumors [1] - This product marks the company's first embolization product in the field of tumor interventional therapy, with the registration certificate valid from January 28, 2026, to January 27, 2031 [1] - The company has multiple other tumor interventional products that have been approved or are under research, but actual sales will depend on market promotion efforts, making future revenue impact unpredictable [1]

中国国际金融股份有限公司 关于上海微创心脉医疗科技（集团）股份有限公司 2025 年度持续督导工作现场检查报告 根据《证券发行上市保荐业务管理办法》《上海证券交易所上市公司自律监管指引 第11号——持续督导》等有关法律、法规的规定，中国国际金融股份有限公司（以下简 称"保荐机构"、"中金公司"）作为正在履行上海微创心脉医疗科技（集团）股份有 限公司（以下简称"心脉医疗"、"公司"）持续督导工作的保荐机构，对公司2025年 1月1日至2025年12月31日期间（以下简称"本持续督导期间"）的规范运作情况进行了 现场检查，现就现场检查的有关情况报告如下： 一、本次现场检查的基本情况 （一）保荐机构：中国国际金融股份有限公司 （五）现场检查内容：公司治理及内部控制、信息披露、独立性、与关联方的资金 往来、募集资金使用情况、关联交易、对外担保、重大对外投资、公司经营状况等。 （六）现场检查手段:对公司董事会秘书、财务总监等进行访谈；查看公司主要经 营、管理场所；查阅并取得公司公告、公司治理文件、重大合同、公司定期报告等文件； 查阅并取得公司募集资金使用凭证等原始凭证、募集资金专户银行对账单等资料；查阅 公司本持续督导 ...

Core Viewpoint - The stock of Xinmai Medical (688016) has shown a slight increase, with a closing price of 99.25 yuan on February 5, 2026, reflecting a 1.66% rise, while the overall market sentiment indicates mixed capital flows with significant retail investor inflow [1][5]. Financial Performance - Xinmai Medical reported a total revenue of 1.015 billion yuan for the first three quarters of 2025, representing a year-on-year increase of 4.66% [4]. - The net profit for the same period was 429 million yuan, showing a year-on-year decline of 22.46% [4]. - The gross profit margin stands at 70.4%, significantly higher than the industry average of 50.55% [4]. Market Position - Xinmai Medical's total market capitalization is 12.234 billion yuan, which is above the industry average of 11.126 billion yuan, ranking 27th out of 128 companies in the medical device sector [4]. - The company has a price-to-earnings (P/E) ratio of 21.38, which is considerably lower than the industry average of 93.58, ranking 13th in the industry [4]. Capital Flow Analysis - On February 5, 2026, the net outflow of main funds was 10.8214 million yuan, accounting for 4.87% of the total transaction amount, while retail investors saw a net inflow of 15.6052 million yuan, representing 7.02% of the total [1][2]. - Over the past five days, the stock has experienced fluctuating capital flows, with notable retail investor activity during periods of price increases [1][2]. Institutional Ratings - In the last 90 days, four institutions have issued buy ratings for Xinmai Medical, with an average target price of 122.06 yuan [5].

Group 1 - The core viewpoint of the news is that Xinmai Medical has seen a continuous increase in its stock price, with a 7.53% rise over three days, reaching 99.25 CNY per share, and a total market capitalization of 12.234 billion CNY [1] - Xinmai Medical, established on August 17, 2012, and listed on July 22, 2019, specializes in the research, production, and sales of interventional medical devices for aortic and peripheral blood vessels [1] - The company's main business revenue composition is as follows: 71.94% from aortic products, 28.04% from peripheral and other products, and 0.02% from other sources [1] Group 2 - According to data from the top ten holdings of funds, one fund under Xinhua Fund holds shares in Xinmai Medical, specifically the Xinhua Strategic Emerging Industries Flexible Allocation Mixed Fund (001294), which has maintained its holding of 24,700 shares [2] - The fund's holding represents 4.28% of its net asset value and is the eighth largest holding, with a floating profit of approximately 40,000 CNY today and 171,700 CNY during the three-day increase [2] - The Xinhua Strategic Emerging Industries Flexible Allocation Mixed Fund was established on June 29, 2015, with a latest scale of 52.9542 million CNY, and has achieved a year-to-date return of 3.07% [2]

国机重装：2025年度净利润同比增长10.89% 利亚德：拟不超1亿元投资产业基金，后者将定向投资商业航天（核心股）领域的非上市公司 【经营合作】 【增持回购】 长安汽车：拟以10亿元-20亿元回购公司股份 【业绩】 【重要事项】 股票频道更多独家策划、专家专栏，免费查阅>> 责任编辑：栎树 盛新锂能：全资子公司盛屯锂业拟12.6亿元收购惠绒矿业13.93%股权 广东建工：联合体中标15.24亿元年产2GWh三维固态锂电池（核心股）智能制造生产基地项目 中船防务：签订16艘支线集装箱船建造合同，金额7.36亿美元至8.96亿美元 中文在线：拟与腾讯计算机就动画微短剧授权合作事宜达成合作 东华科技：与青海东台吉乃尔锂资源股份有限公司签订战略合作框架协议 上海医药（核心股）：拟不低于10.23亿元公开挂牌转让中美施贵宝30%股权 中船防务：签订16艘支线集装箱船建造合同 金额7.36亿美元至8.96亿美元 银邦股份：收到Holtec公司约2.8亿元销售订单 斯莱克：控股子公司获韩国电池客户项目定点 惠博普：签订约15.96亿元Naft Khana油田复产项目合同 北新路桥：联合体中标11.45亿元工程项目 康恩贝 ...

Group 1 - Sileck's subsidiary received a project designation letter from a South Korean battery customer, expected to supply approximately 360 million cylindrical battery shells from 2027 to 2031 [1] - Fuguang Co.'s major shareholder plans to reduce its stake by up to 3%, amounting to a maximum of 481.68 million shares [2] - Beixin Road and Bridge's consortium won a contract for a project worth 1.145 billion yuan, with two segments valued at 223.1 million yuan and 921.5 million yuan respectively [3] Group 2 - Jianyou Co.'s subsidiary received FDA approval for sodium selenite injection, aimed at providing selenium for parenteral nutrition in adults and pediatric patients [4] - China Galaxy received approval to publicly issue subordinated bonds totaling up to 20 billion yuan [6] - Changjiang Electric Power announced a cash dividend of 0.21 yuan per share, totaling 5.138 billion yuan [7] Group 3 - Zhongjin Company received approval to publicly issue corporate bonds totaling up to 20 billion yuan [8] - Daon Co. received a decision from the State Administration for Market Regulation not to conduct further antitrust review on its acquisition of Ningbo Aisikai Synthetic Rubber Co. [10] - Palm Co. won a project worth approximately 228 million yuan, which is expected to account for 7.44% of its audited revenue for 2024 [11] Group 4 - Kang En Bei's subsidiary received approval for clinical trials of TFA003 tablets for diabetic nephropathy [13] - Xinmai Medical's subsidiary obtained a medical device registration certificate for polyvinyl alcohol embolization microspheres [14] - Guangsheng Tang's innovative hepatitis B drug completed the enrollment of 578 participants in its Phase III clinical trial [15] Group 5 - Pianzaihuang's controlling shareholder received a loan commitment for up to 450 million yuan to support share buybacks [16] - Liya De plans to invest up to 100 million yuan in an industry fund focused on commercial aerospace [17] - Zhongwen Online plans to collaborate with Tencent on animation micro-short drama licensing, with an expected cooperation amount of 23.2 million yuan [19] Group 6 - Yungsheng Technology is planning to acquire control of Fengrui Fluorine Industry, with its stock continuing to be suspended [22] - Yinbang Co. received a sales order from HOLTEC ASIA for approximately 280 million yuan, expected to positively impact its operations in 2026 and 2027 [23] - Pailin Bio's subsidiary received a drug registration acceptance notice for human coagulation factor IX [24] Group 7 - Dao Dao Quan plans to apply for soybean oil delivery warehouse qualifications from the Dalian Commodity Exchange [25] - Qizheng Tibetan Medicine's subsidiary received a registration certificate for a traditional Chinese medicine product in Macau [26] - Vili Medical received EU MDR certification for multiple products [27][28] Group 8 - CITIC Bank plans to increase its investment in its wholly-owned subsidiary by 2 billion yuan [29] - Hayao Co. received approval for the consistency evaluation of its injectable drugs [30] - Zhifei Biological's freeze-dried varicella vaccine clinical trial received approval [31] Group 9 - Huibo Pu signed a contract worth 225 million USD for the Naft Khana oilfield recovery project [32] - Zhonggu Logistics plans to invest in the construction of two 6000 TEU container ships, with a total contract amount not exceeding 1.16 billion yuan [33] - Chongqing Beer reported a 10.43% increase in net profit for 2025, with revenue of 14.722 billion yuan [34] Group 10 - Huanxu Electronics reported a 12.16% increase in net profit for 2025, with revenue of 59.195 billion yuan [35] - Chengzhi Co.'s subsidiary successfully completed trial production of a high molecular weight polyethylene project [36] - Guangyang Co. signed a strategic cooperation agreement with Shenzhen Xuanchuang and Huangshan Guangyang [37]

Core Viewpoint - The company Xinmai Medical (688016.SH) announced that its wholly-owned subsidiary, Shanghai Tuomai Medical Technology Co., Ltd. (referred to as "Tuomai Medical"), has received a medical device registration certificate from the National Medical Products Administration for polyvinyl alcohol embolization microspheres, which are intended for the embolization treatment of hypervascular malignant tumors in solid organs [1] Group 1 - The product is specifically designed for the treatment of hypervascular malignant tumors [1] - The registration certificate was issued by the National Medical Products Administration [1] - The product represents a significant advancement in the company's medical device offerings [1]

Group 1 - The core point of the article is that Shanghai MicroPort MedBot (Group) Co., Ltd.'s wholly-owned subsidiary, Shanghai Tuomai Medical Technology Co., Ltd., has received a medical device registration certificate from the National Medical Products Administration for its product "Polyvinyl Alcohol Embolization Microspheres" [1] Group 2 - The product "Polyvinyl Alcohol Embolization Microspheres" is a new medical device aimed at enhancing treatment options in the healthcare sector [1]

FinderSphere®/夜明珠™聚乙烯醇栓塞微球是公司在肿瘤介入治疗领域研发 的首款栓塞类产品。该产品将为 TACE 手术提供更精准、更高效的治疗方案选 择，使国内更多肿瘤患者受益。除该款产品，公司在肿瘤介入治疗领域已有 Tipspear®/穿云箭™经颈静脉肝内穿刺套件在国内获批上市，在研产品包括国家创 新医疗器械 HepaFlow®/鹊桥通™TIPS 覆膜支架系统，以及封堵止血系统、微导 管等多款产品。未来，公司将继续致力于主动脉、外周血管及肿瘤介入高端医疗 器械的创新研发和应用推广，让更多国内外患者获益。 三、风险提示 鉴于上述产品需要获得生产许可证后方可上市销售，此外，产品上市后的实 际销售情况取决于未来市场的推广效果，目前尚无法预测上述产品对公司未来营 业收入的具体影响。敬请投资者理性投资，注意投资风险。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 近日，上海微创心脉医疗科技（集团）股份有限公司（以下简称"心脉医疗" 或"公司"）的全资子公司上海拓脉医疗科技有限公司（以下简称"拓脉医疗"） 获得国家药品监督 ...

Core Viewpoint - The company, Xinmai Medical (688016.SH), has received a medical device registration certificate from the National Medical Products Administration for its polyethylene glycol embolization microspheres, marking a significant advancement in interventional oncology treatment options [1] Group 1: Product Development - The polyethylene glycol embolization microspheres, named FinderSphere®/Night Pearl™, are the company's first embolization product developed for interventional oncology [1] - This product aims to provide more precise and efficient treatment options for Transarterial Chemoembolization (TACE) procedures, benefiting a larger number of cancer patients in China [1] Group 2: Existing and Pipeline Products - In addition to the new product, the company has already launched the Tipspear®/Piercing Arrow™ transjugular intrahepatic portosystemic shunt (TIPS) kit in China [1] - The company is also developing several other products in the interventional oncology field, including the innovative medical device HepaFlow®/Bridge to the Sky™ TIPS covered stent system, as well as hemostatic occlusion systems and microcatheters [1] Group 3: Future Commitment - The company is committed to the innovative research and application promotion of high-end medical devices in aortic, peripheral vascular, and interventional oncology fields, aiming to benefit more patients both domestically and internationally [1]